2018
Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study
Butler J, Kalogeropoulos AP, Anstrom KJ, Hsue PY, Kim RJ, Scherzer R, Shah SJ, Shah SH, Velazquez EJ, Hernandez AF, Desvigne-Nickens P, Braunwald E. Diastolic Dysfunction in Individuals With Human Immunodeficiency Virus Infection: Literature Review, Rationale and Design of the Characterizing Heart Function on Antiretroviral Therapy (CHART) Study. Journal Of Cardiac Failure 2018, 24: 255-265. PMID: 29482027, PMCID: PMC5880702, DOI: 10.1016/j.cardfail.2018.02.001.Peer-Reviewed Original ResearchConceptsDiastolic dysfunctionAntiretroviral Therapy studyAntiretroviral therapyMyocardial fibrosisHeart functionMyocardial stressHuman immunodeficiency virus (HIV) infectionAge-matched control subjectsTherapy studiesLV diastolic dysfunctionVentricular systolic dysfunctionImmunodeficiency virus infectionCardiac magnetic resonance examinationHuman immunodeficiency virusMarkers of fibrosisImmune system activationSubclinical myocardial necrosisMagnetic resonance examinationOngoing inflammationSystolic dysfunctionAtrial functionCardiac involvementSystemic inflammationHIV individualsMyocardial effects
2016
Tackling NCD in LMIC Achievements and Lessons Learned From the NHLBI–UnitedHealth Global Health Centers of Excellence Program
Engelgau M, Sampson U, Rabadan-Diehl C, Smith R, Miranda J, Bloomfield G, Belis D, Narayan K, National Health L, Rubinstein A, He J, Alam D, Peters D, Wu Y, Yan L, Merson M, Ramirez M, Caballero B, Xavier D, Yusuf S, Prabhakaran D, Narayan K, Kimaiyo S, Velazquez E, Denman C, Cornejo E, de Zapien J, Rosales C, Miranda J, Gilman R, Levitt N, Gaziano T, Ghannem H, Laatikainen T, Rabadan-Diehl C, Engelgau M, Belis D, Sampson U, Smith R, Dianis N, Wolbach T, Matta G, Gutierrez L, Elorriaga N, Poggio R, Irazola V, Bazzano L, Bhuiya A, Wazed A, Khan A, Siddiquee A, Islam A, Khan J, Uddin J, Hasan K, Khanam M, Yunus M, Chowdhury M, Monalisa N, Alam N, Streatfield P, Ahmed S, Parvin S, Ali T, Niessen L, Hossain M, Koehlmoos T, Standing H, Lucas H, Bleich S, Anderson G, Trujillo A, Mirelman A, Hao J, Zhang J, Tian M, Huang P, Luo R, Fang W, Li X, Feng X, Li Z, Deal K, Peterson E, DeLong E, Zhou B, Shi J, Neal B, Jan S, Li N, McMahon S, Zhang J, Sun J, Elliot P, Zhao Y, Zhang Y, Yao C, Sun N, Han Q, Shen R, Niu W, Wang Y, Ke Y, Huang Y, Leeder S, Lopez A, Zhang R, Yu Y, Roman A, Mendoza C, Roche D, Mejicano G, Cordova M, Kroker M, Fort M, Letona P, Kanter R, Garcia R, Murillo S, Chacon V, Montero R, Lopez E, Peña L, Castro M, Dengo A, Ulate E, Alvarado N, Sibrian J, Alegria A, Gutierrez A, Fontes F, Sigamani A, Kamath D, Xavier F, Deepthi K, Anupama M, Mathu N, George N, Rahul P, Pais P, Girish P, Thomas S, Usha T, Thomas T, Joshi R, Chidambaram N, Gupta R, Chow C, Pogue J, O'Donnell M, Devereaux P, Misquith D, Agrawal T, Fathima F, Reddy K, Shivashankar R, Ajay V, Khan H, Kadir M, Masood M, Fatmi Z, Krishnan A, Singh K, Tandon N, Khadgawat R, Menon V, Sethi B, Unnikrishnan A, Hutcheson M, Ali M, Cunningham S, Patel S, Gujral U, Desai A, Mohan D, Pradeepa R, Mohan V, Viswanathan V, Sahay R, Shah S, Bantwal G, Varthakavi P, Nair M, Akwanalo C, Lagat D, Barasa F, Koech M, Sugut W, Korir B, Mosol P, Ali S, Sherman C, Carter J, Bloomfield G, Binanay C, Vedanthan R, Bernabé-Ortiz A, León-Velarde F, Smith G, Málaga G, García H, Casas J, Sacksteder K, Smeeth L, Huicho L, Rivera M, Gamboa R, Ebrahim S, Montori V, Wise R, Checkley W, Diette G, Nojilana B, Majikela-Dlangamandla B, Sylvester C, Malan J, Murphy K, Steyn K, van Niekerk L, Mash R, Puoane T, Kim G, Pandya A, Abrahams-Gessel S, Rhode H, Pather M, Andrade A, Garcia B, Velasco C, Medina D, Bravo D, Munguia D, Bateman E, Castro F, Schneider H, Ibarra I, Zulu J, Felix J, Tribe K, Bobrow K, Fairall L, Folb N, Murillo N, Pacheco N, Rodriguez P, Navarro P, Flores R, Van Zyl Smit R, Meddoza R, Surka S, Van Haght S, Hernandez Y, Tsolekile L, Jeridi G, Harrabi I, Maatoug J, Boughammoura L, Chaieb L, Mrizek N, Gaha R, Limam K, Amimi S, Gaha K, Gamra H, Al'Absi M, Vartiainen E, Moore C, Spillan D, Cooper K, Mitchell M, Kirby R, Gao Y, Aluko E. Tackling NCD in LMIC Achievements and Lessons Learned From the NHLBI–UnitedHealth Global Health Centers of Excellence Program. Global Heart 2016, 11: 5-15. PMID: 27102018, PMCID: PMC4843818, DOI: 10.1016/j.gheart.2015.12.016.Peer-Reviewed Original ResearchConceptsHealth centersUnitedHealth GroupNoncommunicable disease burdenPriority health issuesBiomedical Research CentreMiddle-income countriesBlood InstituteLung diseaseNational HeartDisease burdenHealth issuesSpecific country settingsCountry settingsProgram’s overall goalSettingFuture investigatorsResearch CenterLungCenterDiseaseNCD
2015
Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial)
Mentz RJ, Hasselblad V, DeVore AD, Metra M, Voors AA, Armstrong PW, Ezekowitz JA, Tang WH, Schulte PJ, Anstrom KJ, Hernandez AF, Velazquez EJ, O'Connor CM. Torsemide Versus Furosemide in Patients With Acute Heart Failure (from the ASCEND-HF Trial). The American Journal Of Cardiology 2015, 117: 404-411. PMID: 26704029, PMCID: PMC4718787, DOI: 10.1016/j.amjcard.2015.10.059.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseAgedCause of DeathDose-Response Relationship, DrugDouble-Blind MethodFemaleFollow-Up StudiesFurosemideGlobal HealthHeart FailureHospitalizationHumansMaleMiddle AgedRetrospective StudiesSodium Potassium Chloride Symporter InhibitorsStroke VolumeSulfonamidesSurvival RateTorsemideTreatment OutcomeConceptsHeart failureChoice of diureticAcute heart failureDecompensated heart failureNatriuretic peptide levelsLow ejection fractionComparative effectiveness trialHF hospitalizationBlood pressureEjection fractionUnadjusted analysesAcute studyClinical effectivenessEffectiveness trialPeptide levelsPatientsFurosemideSimilar outcomesInverse probabilityPotential pharmacologicTorsemideDiureticsMortalityTrialsFailureImportance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction Insights From STICH
Jolicœur EM, Dunning A, Castelvecchio S, Dabrowski R, Waclawiw MA, Petrie MC, Stewart R, Jhund PS, Desvigne-Nickens P, Panza JA, Bonow RO, Sun B, San TR, Al-Khalidi HR, Rouleau JL, Velazquez EJ, Cleland JGF. Importance of Angina in Patients With Coronary Disease, Heart Failure, and Left Ventricular Systolic Dysfunction Insights From STICH. Journal Of The American College Of Cardiology 2015, 66: 2092-2100. PMID: 26541919, PMCID: PMC4655599, DOI: 10.1016/j.jacc.2015.08.882.Peer-Reviewed Original ResearchConceptsCoronary artery diseaseLV systolic dysfunctionGreater survival benefitMedical therapySystolic dysfunctionCause mortalitySurvival benefitWorse prognosisCoronary artery bypass graft surgeryLeft ventricular systolic dysfunctionArtery bypass graft surgeryLong-term clinical outcomesGreater prognostic benefitBypass graft surgeryVentricular systolic dysfunctionEffect of CABGMultivariable CoxSTICH trialGraft surgeryPrognostic benefitArtery diseaseCoronary diseaseEjection fractionHeart failureClinical outcomesImplementation of Management Strategies for Diabetes and Hypertension From Local to Global Health in Cardiovascular Diseases
Bloomfield GS, Wang TY, Boulware LE, Califf RM, Hernandez AF, Velazquez EJ, Peterson ED, Li JS. Implementation of Management Strategies for Diabetes and Hypertension From Local to Global Health in Cardiovascular Diseases. Global Heart 2015, 10: 31-38. PMID: 25754564, PMCID: PMC4754665, DOI: 10.1016/j.gheart.2014.12.010.Peer-Reviewed Original ResearchConceptsCardiovascular diseaseNetwork-based careFuture cardiovascular diseasePopulation risk stratificationUniversity Health CentreSuccessful treatment interventionsChronic conditionsHealth centersTreatment interventionsHypertensionDiabetesImproved healthGlobal healthMajor causal factorDiseaseHealthManagement strategiesCausal factorsPrevalenceCare
2014
Mobile health for non-communicable diseases in Sub-Saharan Africa: a systematic review of the literature and strategic framework for research
Bloomfield GS, Vedanthan R, Vasudevan L, Kithei A, Were M, Velazquez EJ. Mobile health for non-communicable diseases in Sub-Saharan Africa: a systematic review of the literature and strategic framework for research. Globalization And Health 2014, 10: 49. PMID: 24927745, PMCID: PMC4064106, DOI: 10.1186/1744-8603-10-49.Peer-Reviewed Original ResearchMeSH KeywordsAfrica South of the SaharaChronic DiseaseGlobal HealthHealth Services ResearchHumansTelemedicineConceptsNon-communicable disease careDisease careNCD careSystematic reviewMHealth strategiesCochrane Central RegisterRetention of patientsSaharan AfricaNon-communicable diseasesMeta-Analyses (PRISMA) guidelinesPreferred Reporting ItemsEffectiveness of mHealthHealth system challengesWeb of ScienceCentral RegisterComparator armClinical endpointsClinical trialsInclusion criteriaExclusion criteriaInsufficient evidenceReporting ItemsEvidence gapsResultsOur searchMHealth modalities
2010
STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment
Jones RH, White H, Velazquez EJ, Shaw LK, Pietrobon R, Panza JA, Bonow RO, Sopko G, O'Connor CM, Rouleau JL. STICH (Surgical Treatment for Ischemic Heart Failure) Trial Enrollment. Journal Of The American College Of Cardiology 2010, 56: 490-498. PMID: 20670760, PMCID: PMC3259709, DOI: 10.1016/j.jacc.2009.11.102.Peer-Reviewed Original ResearchConceptsLow-risk patientsSTICH trialRAR groupBaseline characteristicsCardiac surgeryIschemic cardiomyopathyHigh-risk patientsNumber of patientsCountry of enrollmentSTICH patientsDuke DatabankRandomization groupTrial enrollmentCardiovascular diseaseRisk differencePatientsClinical decisionTrialsSurgeryCardiomyopathyRiskBroader populationEnrollment performanceDeathThirty-second
2006
Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance
Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of Heart Failure and Left Ventricular Systolic Dysfunction after Acute Myocardial Infarction: Prevalence, Clinical Characteristics, and Prognostic Importance. The American Journal Of Cardiology 2006, 97: 13-25. PMID: 16698331, DOI: 10.1016/j.amjcard.2006.03.005.Peer-Reviewed Original ResearchConceptsVentricular systolic dysfunctionHeart failureSystolic dysfunctionAcute myocardial infarction resultsConcomitant heart failureLong-term mortalityAcute myocardial infarctionMyocardial infarction resultsEvidence-based treatmentsAggressive treatmentClinical characteristicsInhospital deathRehospitalization ratesHospital admissionInfarction resultsPrognostic importanceMyocardial infarctionEarly initiationHigh riskSignificant riskStrongest predictorAdmissionSignificant increaseDysfunctionTreatment
2005
Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT)
Reed SD, Radeva JI, Weinfurt KP, McMurray JJ, Pfeffer MA, Velazquez EJ, Allsbrook JS, Masselink LE, Sellers MA, Califf RM, Schulman KA, Investigators F. Resource use, costs, and quality of life among patients in the multinational Valsartan in Acute Myocardial Infarction Trial (VALIANT). American Heart Journal 2005, 150: 323-329. PMID: 16086938, DOI: 10.1016/j.ahj.2004.08.037.Peer-Reviewed Original ResearchMeSH KeywordsAmbulatory CareAngiotensin II Type 1 Receptor BlockersAngiotensin-Converting Enzyme InhibitorsCaptoprilDrug CostsGlobal HealthHealth Care CostsHealth ResourcesHeart FailureHospital CostsHospitalizationHumansMyocardial InfarctionProspective StudiesQuality of LifeTetrazolesValineValsartanVentricular Dysfunction, LeftConceptsQuality of lifeMyocardial infarctionAcute Myocardial Infarction trialLower medication costsMyocardial Infarction trialHealth-related qualityLinear mixed-effects regression analysisMultinational clinical trialsMixed-effects regression analysisCaptopril groupStudy medicationCardiovascular morbidityVentricular dysfunctionMost patientsHeart failureACE inhibitorsMedication costsProspective economic evaluationClinical trialsHigh riskPatientsValsartanResource useCaptoprilSignificant differences